Early Clinical Findings on ST-001 nanoFenretinide™ Presented at USCLC Annual Workshop 2026 SciTech Development shares promising early-stage clinical data for ST-001 nanoFenretinide™ at the USCLC Workshop 2026, highlighting anti-tumor activity and safety.

Early Clinical Findings on ST-001 nanoFenretinide™ Presented at USCLC Annual Workshop 2026 #United_States #Denver #CTCL #nanoFenretinide #SciTech

SciTech Development Secures $5.5 Million to Advance Cancer Trials with Promising Drug SciTech Development has successfully raised $5.5 million in funding to enhance its cancer clinical trials, showcasing promising results for its innovative drug ST-001.

SciTech Development Secures $5.5 Million to Advance Cancer Trials with Promising Drug #United_States #Detroit #Clinical_Trials #SciTech_Development #nanoFenretinide

SciTech Development's ST-001 nanoFenretinide Enters Next Phase of Clinical Trials for Cancer Treatment SciTech Development has successfully progressed ST-001 nanoFenretinide into the next phase of clinical trials, focusing on its efficacy in treating T-cell Non-Hodgkin Lymphoma.

SciTech Development's ST-001 nanoFenretinide Enters Next Phase of Clinical Trials for Cancer Treatment #USA #Detroit #SciTechDevelopment #nanoFenretinide #T-cellLymphoma